MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)tm Study ? the first national CKD patient registry that captures both ...

Auquan, the market leader in generative AI for deep work in financial services, today announced its Risk Agent, the first and only AI agent that autonomously completes entire risk monitoring and ...

Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were ...

“THIO has consistently and substantially outperformed standard treatment options in our THIO-101 Phase 2 trial to date. THIO-104 will give us direct comparative data from a randomized study in ...

Growing Demand for Thio Chemicals Across Various Industries is Driving the MarketRockville, MD , March 05, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence ...

The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

These harms include online harassment, intimate image abuse, child abuse material, impersonation, deepfakes and hate speech. Read more at straitstimes.com.

SINGAPORE] The first leg of this year’s The Business Times Corporate Golf League is over, and already things are looking ...